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Hey1 is a member of the basic helix-loop-helix–Orange family of transcriptional repressors that mediate
Notch signaling. Here we show that transcription from androgen-dependent target genes is inhibited by Hey1
and that expression of a constitutively active form of Notch is capable of repressing transactivation by the
endogenous androgen receptor (AR). Our results indicate that Hey1 functions as a corepressor for AF1 in the
AR, providing a mechanism for cross talk between Notch and androgen-signaling pathways. Hey1 colocalizes
with AR in the epithelia of patients with benign prostatic hyperplasia, where it is found in both the cytoplasm
and the nucleus. In marked contrast, we demonstrate that Hey1 is excluded from the nucleus in most human
prostate cancers, raising the possibility that an abnormal Hey1 subcellular distribution may have a role in the
aberrant hormonal responses observed in prostate cancer.
Androgens play critical roles in a wide range of developmen-
tal and physiological processes, particularly in male organs
(18). Androgens regulate prostate epithelial cell growth, and
survival and alterations in androgen-dependent signaling con-
tribute to the development of prostate carcinoma, the most
frequently diagnosed neoplasm and the second leading cause
of cancer-related death in men in Western countries (15). The
most common prostate cancer therapy is androgen elimination
combined with antiandrogen treatment. However, most pros-
tate tumors eventually become insensitive to this treatment
and proliferate (9). The elucidation of mechanisms by which
cancers become androgen independent is a crucial step to-
wards developing successful therapies for prostate cancer.
The biological actions of androgens are mediated by the
androgen receptor (AR), a member of the nuclear receptor (NR)
superfamily of ligand-dependent transcription factors (21). NRs
share a common domain structure, comprising an N-terminal
activation domain (activation function 1 [AF1]), a central DNA-
binding domain (DBD), and a C-terminal ligand-binding domain
(LBD) that usually contains a second activation domain (AF2).
Unlike many members of the NR superfamily, the AF1 domain
contributes most of AR transactivation functions. Upon ligand
binding, ARs adopt an active conformation, release chaperone
heat shock proteins, and bind as homodimers to specific DNA
sequences in the promoters of responsive genes, where they re-
cruit cofactors that regulate the transcription of target genes (22).
The ability of NRs to activate gene transcription depends on the
recruitment of coactivator protein complexes with enzymatic ac-
tivities that reorganize chromatin. Among them are members of
the p160 family of coactivators, SRC1, TIF2/GRIP1, and RAC3/
AIB1/ACTR/pCIP (19). The p160 coactivators interact directly
with NRs via conserved LXXLL motifs (10, 28), and they act as
platform proteins recruiting enzymes that catalyze posttransla-
tional modifications in histones, including histone acetyltrans-
ferases (HATs) like CBP/p300 and pCAF and methyltransferases
like CARM-1. The p160 proteins also contribute to the recruit-
ment of ATP-dependent chromatin remodeling complexes (1).
These chromatin modifications are reversible, and corepressor
complexes with opposing enzymatic activities switch off gene tran-
scription and maintain genes in a silenced state. AR, like other
NRs, appears to recruit corepressors that target enzymatic activ-
ities such as histone deacetylases (HDACs) to promoters and
thereby reorganize the chromatin structure to suppress transcrip-
tion. Little is known regarding the mechanisms involved in AR-
dependent gene repression, but recently a number of putative AR
corepressors, including cyclin D1, HBO1, Pyk2, and PIASy, have
been identified (18).
To investigate the function of the highly conserved basic
helix-loop-helix (bHLH)–PAS domain found in the p160 coac-
tivators, we performed a Saccharomyces cerevisiae two-hybrid
screen using the bHLH-PAS domain in SRC1 as bait. Here we
present evidence of a novel functional interaction between
SRC1 and Hairy/Enhancer of split related with YRPW motif 1
(Hey1, also named Hesr1, HERP2, HRT1, and CHF2), a
member of the vertebrate bHLH-Orange (bHLH-O) family of
transcriptional repressors (6). Hey1 interacts directly with
SRC1 and AR and specifically represses transcription from
AR-dependent promoters. Hey1 is a downstream mediator of
Notch-dependent signals, and our findings demonstrate that
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there is a cross talk between the Notch and AR-dependent
pathways in target tissues.
MATERIALS AND METHODS
Two-hybrid screening. Yeast two-hybrid screening, using SRC1 as bait and a
mouse embryo (9.5 to 12.5 dpc) cDNA library, has been described previously (2).
Plasmids. The complete open reading frames of full-length murine Hey1,
human Hey1, human Hey2, and Hey1 deletion mutants (Y [containing amino
acids 1 to 285], YO [amino acids 1 to 115], YOH [amino acids 1 to 49],
and H [amino acids 116 to 299]) were amplified by PCR and subcloned into
pSG5, pGEX-6P-1 (Amersham Pharmacia Biotech), or pSG-Gal (20).
The following plasmids have been described previously: pMT2-MOR, pSG5-
SRC1e, pGL3-2ERE-PS2-LUC, GST-SRC1-(1–450), and pSG5-SRC1-(1–361)
(1); pGL2-Lex-Gal-Luc and pSG5-Lex-VP16 (5); pSVAR (4); AR(1–653) (16);
TAT-GRE-E1B-LUC and Probasin-LUC (29); pSG5-hGR and pSG5-hPR-B
(17); and NICD (amino acids 1747 to 2531 of rat Notch1 subcloned into pEF1-
BOS) (24).
GST pull-down assays. Expression vectors were transcribed and translated in
vitro with [35S]methionine in reticulocyte lysate (Promega). Glutathione S-trans-
ferase (GST) fusion proteins were induced, purified, bound to Sepharose beads
(Amersham), and incubated with translated proteins or whole-cell extracts as
described previously (1) in NETN buffer (20 mM Tris-HCl [pH 8.0], 1 mM
EDTA, 0.5% Nonidet P-40, 100 mM NaCl). After being washed extensively, the
samples were separated on sodium dodecyl sulfate (SDS)–10% polyacrylamide
gels. Gels were fixed and dried, and the 35S-labeled proteins were visualized by
fluorography or blotted onto nitrocellulose and probed with antibodies.
Antibodies. The antibodies used were rabbit anti-human Hey1 affinity-purified
polyclonal antibody (Chemicon International), mouse anti-human monoclonal
AR441 (DAKO), and rabbit polyclonal immunoglobulin G (IgG) anti-GAL4-
DBD (Santa Cruz Biotechnology).
Immunoblotting. Nitrocellulose membranes were blocked in TBS-T (20 mM
Tris-HCl [pH 7.6], 137 mM NaCl, 0.1% Tween 20) containing 3% nonfat milk
powder, washed with TBS-T, and incubated for 2 h with anti-Hey1, anti-AR, or
anti-GAL4-DBD (1:1,000 dilution). After being washed, the membranes were
incubated with goat anti-rabbit horseradish peroxidase or goat anti-mouse horse-
radish peroxidase (1:3,000; DAKO) and washed again with TBS-T. The bound
immunoglobulins were visualized using the ECL detection system (Amersham
Pharmacia Biotech).
Cell culture and transient-transfection experiments. COS-1, HeLa, C2C12,
and MCF-7 cells were cultured in Dulbecco’s modified Eagle’s medium, and
LNCaP cells were cultured in RPMI 1640 supplemented with 10% fetal bovine
serum. Twenty-four hors before transfection, cells were plated in 96-well plates
in phenol red-free medium with 5% dextran charcoal-stripped serum (the serum
was incubated, twice, with activated charcoal and dextran for 30 min at 55°C).
Cells were transfected using FuGENE 6 (Roche). The transfected DNA (mea-
sured in nanograms per well) included the pRL-CMV (Promega) control plas-
mid (1 ng), the reporters TAT-GRE-E1B-LUC (20 ng), Probasin-LUC (20 ng),
pGL3-2ERE-PS2-LUC (10 ng), pGL2-Lex-Gal-Luc (20 ng), and the vectors
pSVAR (5 ng), AR(1–653) (5 ng), pMT2-MOR (2.5 ng), pSG5-hPR-B (5 ng),
pSG5-GR (5 ng), pSG5-SRC1e (10 ng), pSG5-Lex-VP16 (10 ng), pEF-BOS-
NICD (10 ng, except where indicated otherwise), pSG5-Gal4-DBD or pSG5-
Gal-Hey1 fusions (10 ng/well), and pSG5-Hey1 or pSG5-Hey2 (10 ng, except
where indicated otherwise). Empty vectors were used to normalize DNA
amounts. After incubation for 16 h, cells were washed and treated with hormones
for 24 h (10 nM mibolerone for AR, 10 nM 17-estradiol for estrogen receptor
 [ER], 10 nM R5020 for the progesterone receptor [PR], and 10 nM dexa-
methasone for the glucocorticoid receptor [GR]). Cell extracts were assayed for
luciferase activity using a dual reporter assay as described previously (2). The
results shown represent the averages of the results of at least two independent
experiments assayed in quadruplicate plus standard deviations (SD).
Coimmunoprecipitation assay. MCF-7 cells growing in 90-mm-diameter
dishes in phenol red-free medium with 5% dextran charcoal-stripped serum were
transfected with 5 g of NICD plasmid or mock transfected using Lipofectamine
2000 (Invitrogen). After incubation for 5 h, cells were washed and treated with
10 nM mibolerone for 24 h. Cells were washed twice with ice-cold phosphate-
buffered saline and immediately lysed by incubation for 20 min, at 4°C, in IP
buffer (containing 50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Nonidet P-40,
1 mM dithiothreitol, and complete protease inhibitors that were EDTA free
[Roche]). After centrifugation at 14,000  g for 20 min at 4°C, the supernatants
were used for immunoprecipitation with nonimmune rabbit IgG or anti-Hey1
rabbit polyclonal antibody at 4°C for 90 min; immune complexes were then
captured using protein A-Sepharose. Complexes were washed three times with
IP buffer, and proteins were released by boiling the solution for 5 min in SDS
loading buffer. The immunoprecipitated material was separated on SDS–10%
polyacrylamide gels and blotted onto nitrocellulose. The membrane was probed
using anti-AR antibody as described above.
siRNA. hHey1 small interfering RNAs (siRNAs) were from Dharmacon. The
target sequences were 5-AAAAUGCUGCAUACGGCAGGA-3 and 5-AAC
AGUUUGUCUGAGCUGAGA-3. MCF-7 cells were cotransfected in 24-well
plates with both human Hey1 siRNAs (125 ng of each siRNA) or 250 ng of
negative-control siRNA (QIAGEN), 100 ng of TAT-GRE-E1B-LUC and pSG5-
Hey1 (10 ng) or pEF-BOS-NICD (0.5 or 1 ng) using Lipofectamine 2000 (In-
vitrogen) and antibiotic-free medium, as described previously (8). RNA was
extracted using Trizol (GIBCO), and Hey1 expression was studied by real-time
PCR. The primer sequences were 5-GCTGGTACCCAGTGCTTTTGAG-3
and 5-TGCAGGATCTCGGCTTTTTCT-3. For luciferase assay, after trans-
fection, cells were washed and incubated in fresh medium for 16 h. Subsequently,
cells were incubated for 24 h with vehicle or 10 nM mibolerone. Cell lysates were
then assayed using a dual luciferase reporter system
Immunohistochemistry. Prostate samples from 24 separate patients with pros-
tate cancer or benign prostatic hyperplasia (BPH) were collected at surgery with
the approval of St. Mary’s National Health Service Trust local research ethics
committee. Four-micrometer-thick sections of formalin-fixed, paraffin-embed-
ded prostate tissue were dewaxed in xylene and rehydrated in decreasing con-
centrations of ethanol, and endogenous peroxidase activity was blocked using 2%
hydrogen peroxide. Antigen retrieval was carried out by microwaving at 750 W
in 0.01 M trisodium citrate, pH 6, three times for 5 min. Sections were blocked
with goat serum (1:10 dilution) before incubation overnight at 4°C with the
primary antibody: rabbit polyclonal anti-human AR441 (1:150 dilution) or rabbit
anti-human Hey1 (1:1,000 dilution). After being washed, sections were incubated
with biotinylated goat anti-rabbit IgG (1:200, 45 min; DAKO), followed by
peroxidase conjugated with streptavidin (1:100, 30 min; DAKO). Sections were
then washed, and enzyme activity was developed in 1 mg of 3,3-diaminobenzi-
dine tetrahydrochloride (DAKO) per ml and counterstained with hematoxylin
(Vector Laboratories).
RESULTS
Hey1 interacts with SRC1 and AR. We have previously em-
ployed a yeast two-hybrid screen to identify proteins that in-
teract with the bHLH-PAS domain of SRC1 (2). One of the
clones encodes full-length Hey1, a member of the bHLH-O
family of transcriptional repressors. The specificity of the in-
teraction was confirmed by retransforming yeast with expres-
sion vectors for the fusion proteins shown in Fig. 1A. The
increase in -galactosidase indicates that the bHLH-PAS do-
main of SRC1 interacts with Hey1 in intact cells. We also
confirmed that the bHLH-PAS domain was able to interact
with Hey 1 in vitro by using GST pull-down assays (Fig. 1B).
However, an in vitro-translated SRC1 deletion mutant com-
prising the bHLH domain and only half of the PAS domain
(amino acids 1 to 199) (Fig. 1A) showed no interaction with
Hey1 (Fig. 1B). This result indicates that the interaction re-
quires an intact PAS domain and does not reflect only an
interaction between the HLH domains present in both pro-
teins. Expressed sequence tag databases indicate that Hey1 is
highly expressed in prostate, an androgen-dependent tissue.
Furthermore, the observation that AR interacts with amino-
terminal enhancer of split (31), a member of the transducin-
like enhancer of split family of transcriptional repressors,
downstream effectors for several members of the bHLH-O
family, prompted us to determine whether Hey1 was able to
interact with AR. Using GST pull-down experiments, we de-
tected a specific interaction between in vitro-translated full-
length AR and GST-Hey1 (Fig. 1C) that was unaffected by the
presence of AR agonists or antagonists. Similarly, endogenous
AR, expressed in LNCaP prostate cells, bound to GST-Hey1 in
a ligand-independent manner (Fig. 1D).
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FIG. 1. Hey1 interacts with SRC1 and AR. (A) The L40a yeast strain expressing either LexA-DBD (LexA) or LexA-DBD fused to the SRC1
bHLH-PAS domain (PAS) was transformed with either an empty pASV3 plasmid (VP16) or pASV3 expressing Hey1 fused to the VP16 activation
domain (Hey1). -Galactosidase activity in each yeast extract was measured in duplicate. Data represent the means  SD of results with two
independent transformants. The schematic representation of the LexA chimera used as bait in the yeast two-hybrid screening is shown above.
(B) Hey1 interacts in vitro with the SRC1 bHLH-PAS domain. GST fusion proteins coupled with Sepharose beads were incubated with in
vitro-translated (ivt) [35S]methionine-labeled Hey1 or SRC1 fragments as indicated. After being washed extensively, samples were boiled and
separated by SDS–10% polyacrylamide gel electrophoresis. Gels were fixed and dried, and the labeled proteins were detected by fluorography. AA,
amino acids. (C) Hey1 interacts in vitro with AR. GST alone or GST-Hey1 were incubated with 35S-labeled AR, in the presence of vehicle (),
100 nM mibolerone (Mb), or 10 M Casodex (Cx). (D) Whole-cell extracts from LNCaP cells were incubated with GST alone or GST-Hey1 bound
to glutathione-Sepharose in the presence of vehicle () or 100 nM Mb. The associated AR was detected by immunoblotting using anti-AR
antibody. wb, Western blot. (E) AR and Hey1 colocalize in prostate epithelial cells. Adjacent sections of human BPH samples were stained with
anti-AR antibodies (top panels) or anti-Hey1 antibodies (bottom panels). Two different magnifications are shown (scale bar	 100 m). The brown
color reflects positive staining for AR or Hey1, and negative nuclei are blue.
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Next we investigated whether Hey1 and AR are expressed in
the same regions in the prostate. We analyzed sections of
human BPH by immunostaining and detected both proteins in
luminal epithelial cells (Fig. 1E). Taken together our data raise
the possibility that Hey1 may be involved in the regulation of
AR activity.
Hey1 represses AR-dependent gene expression. In view of
the interaction between Hey1 and AR, we tested the effect of
Hey1 expression on the ability of AR to stimulate transcription
from luciferase reporter genes in transfected cells. The expres-
sion of Hey1 reduced ligand-dependent activation from two
androgen-responsive promoters, Probasin-LUC and TAT-
GRE-E1B-LUC (Fig. 2A). Basal transcription from the Pro-
basin-LUC reporter was also reduced in the presence of Hey1,
but only in the presence of AR (data not shown), indicating
that the repression was specific for the AR and not a general
effect. Another member of the Hey family, Hey2, was also able
to repress AR-dependent transcriptional activity from the two
androgen-responsive promoters tested, indicating that the high
homology at sequence level reflects similar functional charac-
teristics (Fig. 2B).
To investigate whether Hey1 and Hey2 were able to function
as corepressors for other steroid receptors, we examined tran-
scription from the TAT-GRE-E1B-LUC reporter in the pres-
ence of the progesterone receptor (PR) or the glucocorticoid
receptor (GR). Both these receptors stimulated the reporter
gene in the presence of their cognate ligands, but neither Hey1
(Fig. 2C, left panel) nor Hey2 (data not shown) were inhibi-
tory. Similarly, we found that Hey1 did not repress the tran-
scriptional activity of estrogen receptor  (ER) (Fig. 2C, right
panel). Although these receptors were insensitive to the inhib-
itory effects of Hey1, we were able to detect a very weak
interaction between them in GST pull-down assays (data not
shown), which is presumably insufficient to mediate repression.
Therefore, we conclude that the AR is the only steroid recep-
tor sensitive to the inhibitory effects of Hey1.
Hey1 represses AR activation function-1. AR contains two
activation domains, AF1, which seems to be responsible for
most of AR transcriptional activity (reference 3 and references
therein) and AF2 in the LBD. To investigate the interaction
between Hey1 and these domains, we used GST pull-down
experiments (constructs are shown in Fig. 3A) and found that
GST-AF1, but not GST-AF2, bound in vitro-translated full-
length Hey1 (Fig. 3B).
Deletion of the LBD results in a constitutively active recep-
tor that activates ARE-containing reporters in a ligand-inde-
pendent manner with the same potency as the full-length AR
(27). We investigated whether this AF1-dependent transcrip-
tional activity is sensitive to Hey1 repression. When we co-
transfected AR(1–653) together with TAT-GRE-E1B-LUC or
Probasin-LUC, there was a marked increase in luciferase ac-
tivity that was dramatically reduced when Hey1 was coex-
pressed (Fig. 3C). These results suggest that the ability of Hey1
to inhibit AR activity is mediated by a functional interaction
with AF1.
Hey1 overcomes SRC1 coactivation of AR. Given the inter-
action between SRC1 and Hey1, we investigated whether there
was a functional link in transiently transfected COS-1 cells.
SRC1 promotes the ability of AR to stimulate transcription
from the TAT-GRE-E1B-LUC reporter gene (Fig. 3D), but
FIG. 2. Hey1 represses AR-mediated transactivation in vivo.
(A) COS-1 cells were cotransfected with 20 ng of TAT-GRE-E1B-
LUC or Probasin-LUC and expression vectors for AR (5 ng) and Hey1
(10 ng). (B) COS-1 cells were cotransfected with 20 ng of TAT-GRE-
E1B-LUC or Probasin-LUC and expression vectors for AR (5 ng) and
Hey2 (10 ng). (C) COS-1 cells were cotransfected with 20 ng of TAT-
GRE-E1B-LUC and expression vectors for Hey1 (10 ng) and PR (5
ng) or GR (5 ng), or with 10 ng of 2ERE-pS2-LUC and expression
vectors for ER (2.5 ng) and Hey1 (10 ng). After transfection, cells
were washed and incubated for 24 h in the presence of vehicle (white
bars) or a 10 nM concentration of hormones (gray bars; mibolerone for
AR, 17-estradiol for ER, R5020 for PR, and dexamethasone for
GR). Subsequently, cell lysates were assayed using a dual luciferase
reporter system. Normalized values are expressed relative to the ac-
tivity of AR, PR, GR, or ER alone in the presence of their respective
ligands. The results shown represent the averages of results of at least
two independent experiments assayed in quadruplicate  SD.
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this was abolished in a dose-dependent manner when Hey1 was
expressed. Interestingly, Hey1 did not affect the ability of
SRC1 to potentiate transcriptional activation by ER (Fig.
3D), suggesting that Hey1 does not merely sequester SRC1 to
prevent activation. Our results indicate that the ability of SRC1
to function as an AR coactivator depends on the relative con-
centration of Hey1 by a mechanism that does not affect other
steroid receptors. According to our previous results, Hey1
seems to target AF1 in the AR; therefore, we investigated
whether Hey1 was able to overcome SRC1 coactivation of the
deletion mutant AR(1–653), which lacks AF2. Hey1 inhibited
SRC1 coactivation of the AR deletion mutant in a dose-de-
pendent manner (Fig. 3E), again suggesting a role for Hey1 in
the modulation of AR activity through the AF1 domain.
Characterization of Hey1 as a transcriptional repressor.
Hey1, Hey2, and HeyL form the HEY subfamily of transcrip-
tional repressors (12). To characterize the repressive activity of
Hey1, we investigated its ability to repress in trans the activity
of a strong transcription factor in a trans-repression assay.
Seven LexA and five Gal4 binding elements were fused in
tandem upstream of a luciferase reporter (Fig. 4A). Then, the
VP16 transcription factor fused to LexA-DBD was cotrans-
fected with Gal4-DBD alone as a control or with Gal4-DBD
fused to full-length Hey1 or deletion mutants. The strong lu-
ciferase activity induced by LexA-VP16 was dramatically re-
duced in the presence of a Gal4-Hey1 fusion, whereas expres-
sion of Gal4-DBD alone affected the luciferase activity only
marginally (Fig. 4A). In order to determine the contribution of
individual regions of the protein to the repression observed in
our assay, we fused Hey1 deletion mutants to GAL4-DBD.
Western blotting control experiments showed that all deletion
mutants were expressed at similar levels (data not shown). The
deletion of the YRPW motif (Gal-Y) or both YRPW and the
orange domain (Gal-YO) did not significantly reduce the
repression of LexA-VP16 activity (Fig. 4A). However, further
C-terminal deletion of the HLH domain (Gal-YOH)
completely abolished the repression (Fig. 4A). Interestingly,
the N-terminal deletion mutant lacking the HLH domain (Gal-
FIG. 3. Characterization of Hey1 as an AR corepressor. (A-C) AF1 activity is repressed via direct interaction with Hey1. (A) Schematic
representation of full-length AR and deletion mutants. (B) Binding of GST fusion proteins of AR deletion mutants to 35S-labeled Hey1. Where
appropriate, assays were performed in the presence of vehicle () or 100 nM mibolerone (Mb). Bound proteins were visualized as described in
the legend for Fig. 1B. ivt, in vitro translated. (C) COS-1 cells were cotransfected with 20 ng of TAT-GRE-E1B-LUC or Probasin-LUC and
expression vectors for Hey1 (10 ng) and AR(1–653) (5 ng). (D) Hey1 overcomes SRC1 coactivation of AR. COS-1 cells were cotransfected with
20 ng of TAT-GRE-E1B-LUC and expression vectors for AR (5 ng) and SRC1e (10 ng) or with 10 ng of 2ERE-pS2-LUC and expression vectors
for ER (2.5 ng) and SRC1e (10 ng). In each case, increasing amounts of the Hey1 expression vector (5, 10, or 20 ng) were added. (E) Hey1
overcomes SRC1 coactivation of AR AF1. COS-1 cells were cotransfected with 20 ng of TAT-GRE-E1B-LUC, expression vectors for AR(1-653)
(5 ng) and SRC1e (10 ng), and increasing amounts of the Hey1 expression vector (5, 10, or 20 ng). After transfection, cells were washed and
incubated for 24 h in the presence of vehicle (white bars) or a 10 nM concentration of hormones (gray bars; 10 nM mibolerone for AR and
17-estradiol for ER). Subsequently, cell lysates were assayed using a dual luciferase reporter system. Data are presented as described for Fig.
2. The results shown represent the averages of results of two independent experiments assayed in quadruplicate  SD.
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H) repressed the luciferase activity observed by 70% (Fig.
4A). These results indicate that Hey1 contains at least two
distinct repressive domains, one in the N-terminal region and
the second in the C-terminal half of the protein.
To investigate whether HDACs play a role in Hey1-medi-
ated repression, we performed the trans-repression experi-
ments with full-length Hey1 or deletion mutants in the pres-
ence of the HDAC inhibitor Tricostatin A (TSA). The
repression activity of Gal-H was completely reversed by TSA
treatment, whereas that of full-length Gal-Hey1, Gal-Y, and
Gal-O was only partially reversed (30 to 40%) (Fig. 4B).
These observations suggest that multiple repression mecha-
nisms contribute to the repression by full-length Hey1. We
conclude that the C-terminal repression domain in Hey1,
which is TSA sensitive, is HDAC dependent but that the re-
pression by the HLH domain may involve both HDAC-depen-
dent and HDAC-independent mechanisms.
Contribution of Hey1 domains to the repression of AR. We
then investigated which repressive domains in Hey1 were re-
quired for the transcriptional repression of AR using Hey1
deletion mutants corresponding to the same regions fused to
GAL4-DBD in the trans-repression assay. The C-terminal de-
letion mutant lacking the YRPW motif repressed AR activity
to the same degree as full-length Hey1 in both reporters tested
(Fig. 5A). Surprisingly, none of the other deletion mutants,
even those with intrinsic repressive properties, significantly
inhibited AR-dependent reporter activity (Fig. 5A). A similar
level of expression was observed for all deletion mutants in
FIG. 4. Characterization of Hey1 as a transcriptional repressor. (A) Mapping of autonomous repression domains in Hey1. HeLa cells were
cotransfected with 20 ng of pGL2-Lex-Gal-Luc and expression vectors for LexA-VP16 (10 ng) and Gal4-DBD fusion proteins (10 ng) as indicated.
(B) Effects of HDAC inhibitors in Hey1-mediated repression. COS-1 cells were cotransfected as indicated above before being incubated for 24 h
in the presence of a vehicle (gray bars) or 500 nM TSA (white bars). Subsequently, cell lysates were assayed using a dual luciferase reporter system.
Normalized values are expressed relative to the activity observed in the presence of LexA-Vp16 alone. The results shown represent the averages
of results of two independent experiments assayed in quadruplicate  SD.
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control Western blotting experiments (data not shown). To
check whether the lack of repression by Hey1 deletion mutants
simply reflected the loss of the domains required for the inter-
action with AR and/or SRC1, we fused the same Hey1 regions
to GST and performed in vitro GST pull-down experiments.
Only the mutant GST-YOH failed to interact with in
vitro-translated AR, and all the mutants interacted to some
extent with the in vitro-translated SRC1-PAS domain (Fig.
5B). Thus, the mutants Gal-YO and Gal-H, which contain
intrinsic repressive domains and interact in vitro with AR and
SRC1, do not inhibit AR-dependent transcriptional activity.
These observations suggest that Hey1 requires the concerted
action of both the N-terminal bHLH and the C-terminal re-
pression domains in order to act as a corepressor for the AR.
Activation of Notch pathways represses AR-dependent gene
expression. Hey1 is known to be a target gene for Notch
signaling in C2C12 cells (13). Given the reported increase in
expression and nuclear accumulation of Hey1 upon Notch
activation, we investigated whether expression of the Notch
intracellular domain (NICD), which is constitutively active,
would inhibit the ability of AR to stimulate transcription. We
found that expression of NICD dramatically inhibited AR-
dependent transcriptional activity. This repression was even
more potent than that caused by Hey1 (Fig. 6A), perhaps
reflecting the induction of other repressors, like Hes1, known
to synergistically cooperate with Hey1 to repress gene tran-
scription (14). Since our C2C12 cell line does not express
functional AR, we screened cell lines reported to be AR pos-
itive, including LNCaP, ZR-75-1, and MCF-7 cells, for expres-
sion of both AR and Hey1, as judged by real-time PCR (data
not shown) and found that only the human breast cancer
MCF-7 cell line fulfilled these criteria. The ability of endoge-
nous AR to stimulate transcription from the TAT-GRE-E1B-
LUC reporter gene in these cells was markedly reduced in the
presence of increasing amounts of NICD (Fig. 6B) and again
the repression was greater than that observed transfecting
Hey1 (Fig. 6D). NICD also inhibited endogenous PR-depen-
dent transcription in MCF-7 cells (Fig. 6C). However, Hey1
did not inhibit PR in this cell line (Fig. 6E), in agreement with
the results observed with COS-1 cells (Fig. 2C), suggesting that
FIG. 5. Contribution of Hey1 domains to the repression of AR-dependent transcriptional activity. (A) COS-1 cells were cotransfected with 20
ng of TAT-GRE-E1B-LUC or Probasin-LUC reporters and expression vectors for AR (5 ng) and Hey1 (10 ng) deletion mutants. After
transfection, cells were washed and incubated for 24 h in the presence of vehicle (white bars) or 10 nM mibolerone (gray bars). Subsequently, cell
lysates were assayed using a dual luciferase reporter system. Data are presented as described for Fig. 2. The results shown represent the averages
of results of two independent experiments assayed in quadruplicate  SD. (B) In vitro interaction of Hey1 deletion mutants with AR and SRC1.
GST fusion proteins of full-length Hey1 or deletion mutants were incubated with 35S-labeled AR or the SRC1 bHLH-PAS domain. Bound proteins
were visualized as described in the legend for Fig. 1B. ivt, in vitro translated; AA, amino acids.
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the repressive effect of Hey1 is selective for the AR. NICD is
not a general repressor for all steroid receptors because in
parallel experiments we observed that expression of NICD did
not affect ER-dependent transcription (data not shown). We
confirmed that endogenous levels of Hey1 mRNA increased
when we overexpressed constitutively active NICD in MCF-7
cells (data not shown). According to our previous results, we
predicted that the repressive effect of NICD on AR-dependent
transcription was mediated, at least in part, by Hey1. To test
this possibility, we used siRNAs that reduced Hey1 mRNA by
approximately 60% (Fig. 7A). We found that the Hey1 siRNA
was able to reverse the inhibitory effects of Hey1 (Fig. 7B) and
partially reversed the inhibition induced by Notch activation
(Fig. 7C). It seems likely that this partial reversal reflects the
reduction in endogenous Hey1 levels but may be incomplete
because of the presence of other Hey1 family members or the
residual levels of Hey1 expression. Our results suggest that
there is a functional interaction between the endogenous Hey1
and AR in MCF-7 cells that modulates transcription from
androgen target genes.
The characterization of a cell line coexpressing endogenous
Hey1 and AR provided us with an opportunity to analyze
whether the physical interactions between Hey1 and AR ob-
served in vitro could also occur between the endogenous pro-
teins in intact cells. Upon immunoprecipitation with antibodies
against Hey1 and Western blotting using anti-AR antibodies,
we detected a specific interaction between endogenous AR
and Hey1 in MCF-7 whole-cell extracts (Fig. 8A). NICD ex-
pression had no significant effect on the interaction. Next we
investigated whether this interaction was regulated by the pres-
ence of AR ligands. Consistent with the results presented in
Fig. 1, we found that endogenous Hey1 and AR were able to
interact in the absence of the AR agonist (Fig. 8B), although
there was a slight increase in the presence of the agonist (Fig.
8B). The physical association between endogenous AR and
Hey1 supports our proposal that this interaction plays a role in
the regulation of AR transcriptional activity.
Prostate adenocarcinoma is associated with the nuclear ex-
clusion of Hey1 protein. Amplification of chromosome band 8q
occurs in a large fraction of PCs and correlates with the ag-
FIG. 6. An active form of Notch (NICD) represses AR in vivo. (A) C2C12 cells were cotransfected with 20 ng of TAT-GRE-E1B-LUC and
expression vectors for AR (5 ng), NICD (10 ng), and Hey1 (10 ng). (B and C) MCF-7 cells were cotransfected with 20 ng of TAT-GRE-E1B-LUC
and expression vectors for NICD (0.1, 1, or 5 ng). (D and E) MCF-7 cells were cotransfected with 20 ng of TAT-GRE-E1B-LUC and expression
vectors for Hey1 (10 or 20 ng). After transfection, cells were washed and incubated in fresh medium for 16 h. Subsequently, cells were incubated
for 24 h with vehicle (white bars), 10 nM mibolerone (gray bars), or 10 nM R5020 (black bars). Cell lysates were then assayed using a dual luciferase
reporter system. Data are presented as described for Fig. 2. The results shown represent the averages of results from at least two independent
experiments assayed in quadruplicate  SD.
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gressiveness of tumors (7). Since Hey1 maps to this region, we
examined its expression in a series of such tumors by immu-
nocytochemistry and compared it with a series of genes from
BPH samples (Fig. 9 and data summarized in Table 1), ob-
tained from distinct patients. The expression of AR was also
examined in the same samples. Hey1 expression was detected
in both nuclear and cytoplasmic compartments of epithelial
cells in 13 out 14 BPH samples (Table 1 and Fig. 9A and B, left
panels). The relative proportions varied, but the majority of
BPH samples showed strong nuclear Hey1 expression and nu-
clear exclusion was observed in only one sample. In contrast,
we found that Hey1 was restricted to the cytoplasmic compart-
ment of epithelial cells in 8 out 10 cancer samples (Table 1 and
examples in Fig. 9C and D, left panels). Parallel immunostain-
ing with anti-AR-specific antibody showed that the AR was
localized preferentially in epithelial cell nuclei in both BPH
and prostate cancer samples (Fig. 9A to D, right panels). The
subcellular distribution of Hey1, therefore, does not seem to
influence AR distribution. Hey1 nuclear exclusion was also
observed in perineural invasion (Fig. 9E) and single-cell inva-
sion of stroma (Fig. 9F) by malignant cells in cancer samples.
DISCUSSION
Transcriptional regulation by AR is achieved through inter-
action with cofactors, proteins that are recruited to the AR and
convey the enzymatic activities required for the chromatin
reorganization around the androgen-responsive promoters. In
addition, these cofactors contribute to the regulation of the
assembly and activity of the RNA polymerase II transcription
machinery. Therefore, the identification and characterization
of these transcriptional cofactors is a crucial step towards the
elucidation of the mechanisms that control AR-dependent
gene expression. Here we demonstrate that Hey1 functionally
interacts with the AR, acting as a specific corepressor. Our
data show that Hey1 and AR are expressed in luminal epithe-
lial prostate cells. Androgens play a central role in the control
of proliferation, differentiation, and survival of this subpopu-
FIG. 7. Hey1 siRNA partially reverses the AR repression induced
by the active form of Notch (NICD). (A) Hey1 siRNA decreases Hey1
expression. MCF-7 cells were mock transfected or transfected with 250
ng of a negative control (QIAGEN) or Hey1 siRNAs. Hey1 mRNA
was quantified by real-time PCR. (B) MCF-7 cells were cotransfected
with 100 ng of TAT-GRE-E1B-LUC, 10 ng of the Hey1 expression
vector, and 250 ng of Hey1 siRNAs. *, by Student’s t test, P was 
0.05
(n 	 4). (C) MCF-7 cells were cotransfected with 100 ng of TAT-
GRE-E1B-LUC, expression vectors for NICD (0.5 or 1 ng), and 250 ng
of a negative control (QIAGEN) or Hey1 siRNAs. *, by Student’s t
test, P was 
0.005 compared with values for controls (n 	 6). After
transfection, cells were washed and incubated in fresh medium for
16 h. Subsequently, cells were incubated for 24 h with vehicle (white
bars) or 10 nM mibolerone (gray bars). Cell lysates were then assayed
using a dual luciferase reporter system. Data are presented as de-
scribed for Fig. 2. The results shown represent the averages of results
from at least two independent experiments assayed in quadruplicate 
SD.
FIG. 8. Coimmunoprecipitation of endogenous Hey1 and AR.
(A) MCF-7 cells were mock transfected or transfected with 5 g of
NICD. After transfection, cells were washed and incubated for 24 h.
Whole-cell extracts were then immunoprecipitated with antibodies
against Hey1 (I) or nonimmune IgG (NI). The immunoprecipitated
material was subjected to Western blotting analysis (wb) with anti-AR
monoclonal IgG. (B) Effects of AR agonists in the interaction between
Hey1 and AR. MCF-7 cells were transfected with 5 g of NICD. After
transfection, cells were washed and incubated for 24 h in the presence
of 10 nM mibolerone (Mb) or vehicle () before an immunoprecipi-
tation was performed as described above.
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lation of prostate cells, and alterations in the normal transmis-
sion of androgen-dependent signals initiate the majority of
prostate adenocarcinomas. Our expression analysis uncovered
a striking difference in the subcellular localizations of Hey1 in
patients with prostate cancer and BPH. Most cancer samples
show a total exclusion of Hey1 from the nucleus, whereas
nuclear exclusion was detected in only 1 out of 14 BPH patient
samples.
One of the fundamental challenges for researchers studying
prostate cancer is the understanding of the pathways that lead
FIG. 9. Nuclear exclusion of Hey1 staining in human prostate cancer tissue. Sections of human prostate tissue from patients with benign
prostatic hyperplasia (A and B) or malignant adenocarcinomas of Gleason grades 5 (C) and 3 (D) were stained with anti-Hey1 antibody (left
panels), and sections from the same samples were stained in parallel with anti-AR antibody (right panels). (E and F) Hey1 staining of sections from
malignant epithelial cells infiltrating a nerve sheath (E) and the stromal compartment (F), indicated with arrows. Scale bars, 20 m (A to D) or
100 m (E and F). The brown color reflects positive staining for Hey1 or AR; negative nuclei are blue.
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to the transition to androgen independence in recurrent pros-
tate cancer. Most advanced prostate tumors express AR, sug-
gesting that AR-dependent signals are indispensable for cell
survival. However, these tumors escape hormonal regulation
and become refractory to antiandrogen therapy. Different
models have been proposed to explain the development of
androgen-independent prostate cancer, including mutations in
AR, changes in the levels of AR and/or its coactivators, and
ligand-independent activation of AR through cross talk with
other signaling pathways (for a review, see reference 9). Pros-
tate cancers often contain chromosomal abnormalities, and
indeed a region of chromosome 8 that includes Hey1 is ampli-
fied in the majority of individuals with androgen-independent
prostate cancer. At first sight, the overexpression of an AR
corepressor seems contradictory with most current models pro-
posed to explain androgen-independent prostate cancer, which
postulate an abnormal activation of AR rather than its repres-
sion. However, the amplification of other chromosome 8 genes
may be the critical event during tumorigenesis, and any in-
crease in Hey1 levels may be a bystander effect. Importantly,
the repressive effects of Hey1 in prostate cancer may be evaded
by excluding it from the nucleus. In addition, if Hey1 is re-
quired for the repression of AR in the presence of antiandro-
gens, the cytoplasmic localization of Hey1 may, at least in part,
explain why cancer cells are resistant to antiandrogen treat-
ment.
Unlike most NRs, AF1 is the main domain responsible for
AR transactivation properties, and many corepressors and co-
activators interact preferentially with this region of the recep-
tor. We have demonstrated that Hey1 is recruited to the AR by
means of the AF1, which might explain why agonists or antag-
onists failed to modulate the in vitro interaction between Hey1
and AR. In vivo, the interaction between Hey1 and AR might
be regulated by subcellular localization and the presence of
chaperone proteins that prevent the AR translocating to the
nucleus and interacting with cofactors. Also, AF1 shows high
sequence diversity between different NRs, perhaps explaining
why Hey1 failed to repress other steroid receptors.
The observed interaction between a coactivator and a core-
pressor might seem paradoxical, but it is tempting to speculate
that it may be part of mechanisms that promote the exchange
between coactivator and corepressor complexes when tran-
scription must be switched off. The translocation of Hey1 into
the nucleus may provide prostate cells with a mechanism to
suppress the transmission of endocrine signals.
Hey1 contains at least two domains with cell-independent,
autonomous repressive activity: the N-terminal bHLH region
and the C-terminal half of the protein. Our experiments with
HDAC inhibitors reveal that the bHLH region acts through
HDAC-dependent and HDAC-independent mechanisms. The
second repressive domain seems to be completely HDAC de-
pendent. Interestingly, both isolated domains failed to repress
transcription from androgen-responsive promoters, despite the
fact that they contain autonomous repressive domains and can
still interact in vitro with AR and SRC1. This observation
suggests that Hey1 repression of AR needs the concerted ac-
tion of both repressive domains, indicating a complex regula-
tory mechanism.
The main difference observed in Hey1 expression between
prostate cancer and BPH is the exclusion of Hey1 protein from
the nucleus in malignant cells. Hey1 expression is regulated by
Notch signaling. Upon activation of Notch signaling, Hey1
expression increases and accumulates in the nucleus (11, 13).
Notch pathways regulate cell fate determination mediated by
local cell-cell contact and may play a role in tumorigenesis
(25). Notch1 is expressed in normal prostate epithelial cells
and in prostate cancer cells, and its expression is regulated
during prostate development (26). Overexpression of constitu-
tively active Notch1 inhibits the proliferation of various pros-
tate cells (26), and we observed a dramatic inhibition of AR
activity upon activation of Notch signaling. Transgenic mice
revealed that Notch1-expressing cells may define the progeni-
tor cells in prostate epithelium (30), and gene profiling data
showed that the expression of Notch1 and its ligand jagged1 is
regulated by AR in the prostate (23). Notch1 and jagged1 are
downregulated upon testosterone treatment, and sel-1L, a neg-
ative regulator of Notch, is upregulated (23). These observa-
tions, together with our results, provide a direct link between
an endocrine pathway and Notch signaling, suggesting two-way
negative feedback between AR and Notch pathways. The char-
acterization of these mechanisms and the abnormalities in
Notch signaling leading to Hey1 exclusion from the nucleus
may be critical to the understanding of the development of
androgen-independent prostate cancer.
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